Novel Therapeutics in Chondrosarcoma
|
|
- Adrian Gallagher
- 5 years ago
- Views:
Transcription
1 Novel Therapeutics in Chondrosarcoma Tom Wei-Wu Chen, MD Department of Oncology, National Taiwan University Hospital 5 th Singapore Sarcoma Symposium Oct 7 th, 2017 Photo by Dr. Ting-Hui Wu
2 Overview of bone chondrosarcomas Type % Characteristics Chemo Response a Conventional chondrosarcoma Dedifferentiated chondrosarcoma Mesenchymal chondrosarcoma Clear cell chondrosarcoma ~ 70% IDH-1 or -2 mutation, may arise from enchondroma or Ollier s disease ~20% IDH-1 or 2 mutation (~ 50%), arise from conventional chondrosarcoma; ~ 5% HEY1-NCOA2 translocation; Younger individuals, round cell component 11.5% 20.5% 31% < 2% Chemo-resistant 0% a based on study by Italiano A, et al. Ann Oncol 2013; 24: (n = 180)
3 Ifosfamide may provide survival benefit in dedifferentiated chondrosarcoma Prognostic factor p value HR (95% CI) Ifosfamide ( ) Pathologic fracture Metastasis at diagnosis ( ) ( ) N= 41 Clin Orthop Relat Res Mar;472(3):983-9
4 32Yr female with rib mesenchymal chondrosarcoma and lung metastases treated with doxorubicin-ifosfamide
5 Contents of the next 20 min. Molecular targets that are commonly seen in other cancer treatments PI3k/mTOR and IGF-1 pathways Molecular targets that are more specific to chondrosarcoma biology Hedgehog pathways Isocitrate dehydrogenase (IDH) mutations Immunotherapy
6 Activated IGF-1/PI3K/mTOR pathway in chondrosarcoma Phosphorylated S6 staining in CS IGF-1 PI3K mtorc1 ps6k Clin Cancer Res Jul 15;19(14): ; BoneKEY Reports 2013; (2) Article number 437 Total Positive for ps6 (%) Enchondroma 7 5 (71) Osteochondroma 6 5 (83) Conventional chondrosarcoma Central chondrosarcoma (69) (73) Grade (73) Grade (67) Grade (85) Peripheral chondrosarcoma (58) Grade (64) Grade (56) Grade (33) Dedifferentiated chondrosarcoma (44)
7 Modest activity of single agent mtor inhibitor ridaforolimus in sarcomas (n = 212; 25% bone sarcomas) Median PFS 15.3 wks ORR by RECIST 1.9% Clinical benefit rate 28.8% Chawla S et al. J Clin Oncol 2012; 30:78-84
8 Modest activity of single agent mtor inhibitor ridaforolimus in bone and soft tissue sarcomas as maintenance therapy Median PFS 17.7 vs 14.6 weeks Median OS 90.6 vs 85.3 weeks HR 0.72, p < HR 0.93, p = Demetri GD et al. J Clin Oncol 2013; 31:
9 Cixutumumab (IGF-1R inhibitor) and temsirolimus for patients with bone and soft-tissue sarcoma: Phase II Study Total IGF-1R positive IGF-1R negative CS (53%) 18 (47%) ES (54%) 28 (46%) LMS (58%) 19 (42%) LPS 11 5 (45%) 6 (55%) IGF1+ vs IGF-1 - chondrosarcoma MPNST 11 9 (82%) 2 (18%) MFS 6 1 (17%) 5 (83%) OGS (63%) 19 (37%) UPS 19 9 (47%) 10 (53%) RMS 10 7 (70%) 3 (30%) SFT (58%) 8 (42%) SS (78%) 4 (22%) Schwartz GK et al. Lancet Oncol 2013; 14:371-82
10 Hedgehog pathway is involved in many cancer and also cancer stem cell property Nat Rev Drug Discov 2006; GLI factors FDA Approval: vismodegib to treat metastatic or recurrent locally advanced basal cell carcinoma (Jan 2012)
11 Indian Hedgehog pathway and parathyroid-related peptide (PTHrP) is involved in chondrocyte physiology Growth plate cartilage growth cycle % Patients with High expression of Indian Hedgehog and downstream GLIs Growth plate 4/4 (100%) Cortical bone 2/11 (18%) Osteochondroma 0/4 (0%) Enchondroma 4/4 (100%) Chondrosarcoma 23/23 (100%) Tiet TD et al. Am J Pathol 2006; 168:321-30
12 Hedgehog inhibitors showed some preclinical efficacy in chondrosarcoma xenograft models Am J Pathol 2006; 168:321-30; Mol Cancer Ther 2014;13:
13 Single agent GDC-0449 in advanced chondrosarcoma: single arm phase II study Patient characteristics (n = 45) N (%) Male: Female 31 :14 (69:31) Median age (range) 58.0 ( ) Histological subtype Conventional CS 39 (86.7) Dedifferentiated CS 5 (11.1) Clear cell CS 1 (2.2) Prior lines of chemotherapy 0 25 (55.6) 1 12 (26.7) > = 2 8 (17.8) Italiano A et al. Ann Oncol 2013; 24:
14 Single agent GDC-0449 in advanced chondrosarcoma: single arm phase II study (n=45) The CBR (no progression at 6 months): 25.6% (95% CI ) [Hypothesis CBR 6-month > 40%] Median PFS 3.5 months (95% CI months) Italiano A et al. Ann Oncol 2013; 24: Median OS 12.4 months (95% CI 8.4 not reached months)
15 Some hints of clinical efficacy signal of hedgehog inhibitor Improved growth modulation index (GMI) the ratio of their PFS on GDC-0449 to their PFS on firstline therapy 9 patients (45%) had a GMI > 1; 6 of them (30%) had a GMI 1.3. Target validation Hh overexpression was observed for all patients with SD 6 months for whom data were available (n = 4, 100%, all grade 1 or grade 2) Only 9 out of 16 patients with progressive disease (n = 16, 56%) had Hh overexpression In combination with chemotherapy to reverse drug resistance? Italiano A et al. Ann Oncol 2013; 24:
16 Targeting the metabolic pathway Fumarate hydratase renal cell carcinoma, hereditary leiomyomatosis Succinate dehydrogenase GIST, paraganglioma Isocitrate dehydrogenase (IDH) Semin Cell Dev Biol Jun; 23(4):
17 The role of IDH in normal physiology The role of mutant IDH in carcinogenesis (neomorphism) Cancer Discov 2013; 3: Oncometabolite
18 IDH mutations are commonly found in gliomas, AML, and other specific solid tumors Cancer type IDH1 /2 mutation % AML 15-20% Angioimmunoblastic lymphoma 20% Cholangiocarcinoma 15-20% NEJM 2009; 360;
19 IDH mutation characteristics and hotspot mutations All tumors with IDH1 or IDH2 mutations are heterozygous Nearly all IDH1 or IDH2 mutations cause a single amino acid substitution IDH1 and IDH2 mainly occurs in mutually exclusive manner Clin Cancer Res 2012; 18: ; Trend Mol Med 2010; 16:387-97
20 199 AML patients with IDH2 mutation were treated with single agent IDH2 inhibitor enasidenib 23% of patients experienced CR or CR with partial hematologic recovery lasted a median of 8.2 months Blood Aug 10;130(6):
21 IDH1/2 somatic mutations is common among cartilaginous tumors Tumor type Enchondroma in Ollier/Maffucci Primary central chondrosarcoma Secondary central chondrosarcoma Periosteal chondrosarcoma Dedifferentiated chondrosarcoma % with IDH1/2 mutation 87% Ref Amary et al Pansuriya et al % Amary et al % Amary et al Pansuriya et al % Amary et al % Meijer et al Amary et al Adv Anat Pathol 2013;20:32 38
22 IDH1/2 somatic mutations is common among cartilaginous tumors Tumor type Enchondroma in Ollier/Maffucci Primary central Early chondrosarcoma Event Mutation High Secondary prevalence central in chondrosarcomas Periosteal chondrosarcoma Dedifferentiated chondrosarcoma % with IDH1/2 mutation 87% Ref Amary et al Pansuriya et al % Amary et al % Amary et al Pansuriya et al % Amary et al % Oncogenic driver? Meijer et al Amary et al Adv Anat Pathol 2013;20:32 38
23 Induction of sarcomas by mutant IDH2 IDH2 mut tumor Parental 10T cell IDH2 mutant 10T cell Chao Lu et al. Genes Dev. 2013;27:
24 Decreased 2-HG by IDHi did not lead to decrease in cell viability in solid tumor cell lines Cancer Cell 2015; 28:773-84; Oncotarget 2015; 6:
25 In glioma and AML, IDH1 or IDH2 often noted accompanying other oncogenic mutations Clin Cancer Res; 2016; 22;
26 Ongoing Clinical Trials in IDH1/2 Mutant Tumors Study Agent ID NCT AG-221 NCT NCT NCT AG-881 AG-120 Metformin + chloroquine Mechanism of action Oral IDH2 inhibitor Oral IDH inhibitor Oral IDH inhibitor Oral antidiabetic and oral antimalarial Study design Phase I/II Phase I Phase I Phase Ib Study population Advanced solid tumors, including chondrosarcoma, and angioimmunoblastic T- cell lymphoma, with an IDH2 mutation Advanced solid tumors, including chondrosarcoma, with an IDH1 and/or IDH2 mutation Advanced solid tumors, including chondrosarcoma, with an IDH1 mutation IDH1/2 mutated patients with a glioma, intrahepatic cholangiocarcinoma or chondrosarcoma Status Ongoing, but not recruiting participants Recruiting Recruiting Recruiting
27 2014 PD-1 Tasuku Honjo CTLA-4 James P. Allison Discovery of immune checkpoint molecules
28 Immune Checkpoint Blockade Antigen presenting cell MHC Ag B7 TCR CTLA4 + Cytotoxic T-cell Priming phase + Anti-CTLA4 Tissue cell MHC Ag TCR PDL1 PD1 + Cytotoxic T-cell Effector phase Anti-PD1 Pardoll, Nature Rev Cancer 2012; 12:
29 Safety and Efficacy of PD-1 Blockade Using Pembrolizumab in Patients with <br />Advanced Soft Tissue and Bone Sarcomas: <br />Results of SARC028, a Multicenter Phase II Study
30 Slide 9
31 Slide 21 1 osteosarcoma 1 dedifferentiated chondrosarcoma (1/6 of chondrosarcoma)
32 Slide 24 Presented By Hussein Tawbi at 2016 ASCO Annual Meeting
33 PD-L1 is only expressed in dedifferentiated chondrosarcoma but not in other chondrosarcoma subtypes or benign chondroid tumors Histology n PDL1+ Conventional TMA 157 Osteochondroma 11 0/8 (0%) Peripheral chondrosarcoma Grade I 31 0/25 (0%) Grade II 11 0/10 (0%) Grade III 3 0/3 (0%) Enchondroma 9 0/8 (0%) Central chondrosarcoma Grade I 42 0/40 (0%) Grade II 36 0/28 (0%) Grade III 14 0/13 (0%) Histology n PDL1+ Rare subtypes TMA 66 Clear cell 20 0/20 (0%) Mesenchymal 21 0/19 (0%) Dedifferentiated 25 WD component 17 0/17 (0%) DD component 23 9/22 (41%) Validation cohort 22 Dedifferentiated 22 WD component 15 0/15 (0%) DD component 22 11/21 (52%) Kostine M et al. Modern Pathol 2016; 29:
34 PD-L1 expression limited in dedifferentiated CS part and is associated with TILs DD PD-L1 WD PD-L1 PD-L1 CD3 Kostine M et al. Modern Pathol 2016; 29:
35 Metastatic site and PD-L1 is associated with more immunosuppressive microenvironment Kostine M et al. Modern Pathol 2016; 29: CD8+ T cell (light gray) around 60% of all T cells Metastatic tumors had higher % Tregs Dedifferentiated part with PD-L1 expression also showed high infiltration of M2 macrophages
36 Areas to Improve in the Systemic Therapy for Chondrosarcoma Better method to evaluate treatment efficacy RECIST may not be the best method Degree of differentiation after treatment Growth modulation index The role of cancer immunology in bone sarcomas PD-1/PD-L1 is not the answer What is the sweet spot for chondrosarcoma with IDH mutations Single agent may not be the answer in solid tumors
37 Summary Chemotherapy may provide some benefits in specific subtypes of chondrosarcoma (CS). Molecular targeted agents although provided preclinical anti-tumor activity, clinical studies results were inconsistent or still pending. The best way to reach clinical benefit through drug combinations remains to be eluted. How to accurately assess treatment efficacy and identify molecular or immune targets is crucial in the development of new therapeutics in CS.
38 Special thanks to Dr. Richard Quek and Dr. Mark Puhaindran, Wei Lin Goh The NCCS Team and the ASC Members
THE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network THE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationScientific Perspectives of Olaratumab Beyond the Approval Indication
Scientific Perspectives of Olaratumab Beyond the Approval Indication William D. Tap, MD Chief, Sarcoma Medical Oncology Service Memorial Sloan Kettering Cancer Center GEIS XVI International Symposium October
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER. Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia
IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Distinguishing self from non-self T cells trained in the thymus as
More informationTrabectedin in ASTS. Le Cesne A, et al. J Clin Oncol. 2018;36(suppl): Abstract
Results of a Prospective Randomized Phase III T-SAR Trial Comparing Trabectedin vs Best Supportive Care (BSC) in Patients With Pretreated Advanced Soft Tissue Sarcoma (ASTS) Abstract 11508 Le Cesne A,
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationDisclosures. Immunotherapyin Head & NeckCancer. Actual landscape of systemic treatment in HNSCC. Head andneckcanceris an immunogeneic tumor
Immunotherapyin Head & NeckCancer Disclosures Astra-Zeneca/medimmune: clinical trial BMS: advisory board, clinical trial Merck: advisory board, clinical trial, research funding Carla van Herpen Medical
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationImmune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic
Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationImmunotherapy in head and neck cancer and MSI in solid tumors
Immunotherapy in head and neck cancer and MSI in solid tumors Brian Hunis, MD, MBA Associate Medical Director, Memorial Cancer Institute. Hollywood, FL »No disclosures Objectives»Discuss the role of immunology
More informationImmune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich
Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationEvan J. Lipson, M.D.
Update on treatment for Merkel cell, cutaneous squamous cell and basal cell cancers Evan J. Lipson, M.D. The Johns Hopkins University School of Medicine Bloomberg~Kimmel Institute for Cancer Immunotherapy
More informationTHE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER. Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium
THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium DISCLAIMER Please note: The views expressed within this presentation
More informationNews from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital
News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and
More informationNew Paradigms for Treatment of. Erminia Massarelli, MD, PHD, MS Clinical Associate Professor
New Paradigms for Treatment of Head and Neck cancers Erminia Massarelli, MD, PHD, MS Clinical Associate Professor City of Hope Disclosure Statement Grant/Research Support frommerck Bristol Grant/Research
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationGlioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 1 October 2016 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Immunology in the CNS
More informationImmune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group
Immune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group Results of Phase II Study of Durvalumab and Tremelimumab in recurrent clear cell ovarian cancer Trial
More informationGlioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 27 May 2017 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Challenges in immunooncology
More informationImmunotherapie: algemene principes
Immunotherapie: algemene principes Prof. dr. Evelien Smits Tumorimmunologie, UAntwerpen 14 Oktober 2017, IKG evelien.smits@uza.be Concept of immune evasion Finn O. J. Ann Oncol. 2012 Sep; 23(Suppl 8):
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Cervix
More informationImmunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?
Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE
More informationALK positive Lung Cancer. Shirish M. Gadgeel, MD. Director of the Thoracic Oncology program University of Michigan
ALK positive Lung Cancer Shirish M. Gadgeel, MD. Director of the Thoracic Oncology program University of Michigan Objectives What is ALK translocation? What drugs are used in what sequence? How many times
More informationSarcomas. Living Beyond Cancer A-Z UT Health San Antonio MD Anderson Cancer Center
Sarcomas Living Beyond Cancer A-Z UT Health San Antonio MD Anderson Cancer Center Aaron Sugalski, DO Associate Professor of Pediatric Hematology/Oncology Medical Director, UHS Pediatric Blood and Cancer
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationCheckpoint Blockade in Hematology and Stem Cell Transplantation
Checkpoint Blockade in Hematology and Stem Cell Transplantation Saad S. Kenderian, MD Assistant Professor of Medicine and Oncology Mayo Clinic College of Medicine October 14, 2016 2015 MFMER slide-1 Disclosures
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationRadiation Therapy and Immunotherapy: New Frontiers
Radiation Therapy and Immunotherapy: New Frontiers Nevada Oncology Society Fall Meeting November 16 th, 2017 Anshu K. Jain, MD Radiation Oncologist, Ashland Bellefonte Cancer Center Assistant Clinical
More informationImmunotherapy for dmmr metastatic colorectal cancer. Prof.dr. Kees Punt Dept. Medical Oncology AUMC
Immunotherapy for dmmr metastatic colorectal cancer Prof.dr. Kees Punt Dept. Medical Oncology AUMC Active specific immunotherapy (ASI) in stage II-III colon cancer Vaccination with autologous tumor + BCG
More informationFifteenth International Kidney Cancer Symposium November 4-5, 2016 Marriott Miami Biscayne Bay, Miami, Florida, USA
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More information2018 KSMO Immune Oncology Forum. Immune checkpoint inhibitors in hematologic. malignancies: evidences and perspectives 서울아산병원종양내과 홍정용
2018 KSMO Immune Oncology Forum Immune checkpoint inhibitors in hematologic malignancies: evidences and perspectives 서울아산병원종양내과 홍정용 2018-07-18 Contents Introduction Immune checkpoint inhibtors in lymphomas
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationUpdates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More informationExploring the PD-L1 Pathway
Active Within the tumor microenvironment Steps 1-3: Initiating and propagating anticancer immunity 1 may inhibit T-cell activity in the tumor microenvironment Dendritic cells capture cancer and then prime
More informationOptions for first-line cisplatin-eligible patients
The Past Options for first-line cisplatin-eligible patients Metastatic urothelial cancer Cisplatin-eligible Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin/ gemcitabine Bellmunt
More informationImmunotherapy on the Horizon
Immunotherapy on the Horizon Andrew L. Coveler Assistant Professor of Medicine, Division of Oncology University of Washington Assistant Member Fred Hutchinson Cancer Research Center Image: NASA.gov 1 2
More informationDieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy
More informationPredicting outcome in metastatic breast cancer
Predicting outcome in metastatic breast cancer Aleix Prat, MD, PhD Medical Oncology Department Translational Genomics and Targeted Therapeutics in Solid Tumors Monday, 15 th January, Manchester, UK Disclosures
More informationSummary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain
Summary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain EHA 2017 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://learningcenter.ehaweb.org/eha/#!*listing=3*browseby=2*sortby=1*media=3*ce_id=1181*label=15531
More informationBest Practices in the Treatment and Management of Metastatic Melanoma. Melanoma
Best Practices in the Treatment and Management of Metastatic Melanoma Philip Friedlander MD PhD Director of Melanoma Medical Oncology Program Assistant Professor Division of Hematology Oncology Assistant
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationNobel Prize in Physiology or Medicine 2018
Nobel Prize in Physiology or Medicine 2018 Arunika Mukhopadhaya The Nobel Prize in Physiology or Medicine for the year 2018 was awarded to James P Allison of the United States and Tasuku Honjo of Japan
More informationIMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More informationNew Biological and Immunological Therapies for Cancer
New Biological and Immunological Therapies for Cancer Sant P. Chawla, M.D., FRACP The Sarcoma Oncology Center, Santa Monica CA 90403 7 th International Conference on Drug Discovery &Therapy 1 Promising
More informationFocus on Immunotherapy as a Targeted Therapy. Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct
Focus on Immunotherapy as a Targeted Therapy Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct 18 2018 Disclosures I have nothing to disclose that is relevant to this presentation. Immunology @ Deeley
More informationDCVax Novel Personalized Immune Therapies For Solid Tumor Cancers. SMi 4 th Annual Cancer Vaccines Conference September 16, 2015
DCVax Novel Personalized Immune Therapies For Solid Tumor Cancers SMi 4 th Annual Cancer Vaccines Conference September 16, 2015 Disclaimer Certain statements made in this presentation are forward-looking
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationBasic Principles of Tumor Immunotherapy. Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA
Basic Principles of Tumor Immunotherapy Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA Disclosures Consulting Fees: Biodesix, Novartis Pharmaceuticals Other: Boehringer
More informationINMUNOTERAPIA EN CANCER COLORRECTAL METASTASICO. CCRm MSI-H NUEVO ESTANDAR EN PRIMERA LINEA Y/O PRETRATADOS?
INMUNOTERAPIA EN CANCER COLORRECTAL METASTASICO CCRm MSI-H NUEVO ESTANDAR EN PRIMERA LINEA Y/O PRETRATADOS? V. Alonso Servicio de Oncologia Medica H. U. Miguel Servet Zaragoza MSI-H mcrc Clinical and Pathological
More informationThe Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC
The Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology Baylor College
More informationGenomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy. Raanan Berger MD PhD Sheba Medical Center, Israel
Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy Raanan Berger MD PhD Sheba Medical Center, Israel Disclosures Honoraria, Ad board BMS, MSD, Pfizer, Astra Zeneca, Bayer,
More informationLa chemioterapia neoadiuvante nei sarcomi: novità e attuali indicazioni Lorenzo D Ambrosio, MD PhD Divisione di Oncologia Medica Istituto di Candiolo
La chemioterapia neoadiuvante nei sarcomi: novità e attuali indicazioni Lorenzo D Ambrosio, MD PhD Divisione di Oncologia Medica Istituto di Candiolo Fondazione del Piemonte per l Oncologia. IRCCS 12 CONGRESSO
More informationRole of the Pathologist in Guiding Immuno-oncological Therapies. Scott Rodig MD, PhD
Role of the Pathologist in Guiding Immuno-oncological Therapies Scott Rodig MD, PhD Department of Pathology, Brigham & Women s Hospital Center for Immuno-Oncology, Dana-Farber Cancer Institute Associate
More informationNivolumab in Hodgkin Lymphoma
Nivolumab in Hodgkin Lymphoma Stephen M. Ansell, MD, PhD Professor of Medicine Chair, Lymphoma Group Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers Squibb Celldex Therapeutics Seattle
More informationSupplementary Online Content
Supplementary Online Content Mezquita L, Auclin E, Ferrara R, et al. Association of the Lung Immune Prognostic Index with immune checkpoint inhibitor outcomes in patients with advanced non small cell lung
More informationAdvances in Systemic Therapy Hepatocellular Carcinoma (HCC) Dr ZEE Ying Kiat HASLD Conference Ho Chi Minh City, 18 December 2016
Advances in Systemic Therapy for Hepatocellular Carcinoma (HCC) Dr ZEE Ying Kiat HASLD Conference Ho Chi Minh City, 18 December 2016 Scope Background Staging and treatment strategies Current systemic therapy
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationCONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
More informationESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY
ESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY LUGANO, MAY 4-5, 2018 Clinical development in ovarian cancer C. Sessa, CH CONTENT Rationale for immunotherapy in ovarian cancer Clinical data with single agent immune
More informationObjectives. Briefly summarize the current state of colorectal cancer
Disclaimer I do not have any financial conflicts to disclose. I will not be promoting any service or product. This presentation is not meant to offer medical advice and is not intended to establish a standard
More informationReviewing Immunotherapy for Bladder Carcinoma In Situ
Reviewing Immunotherapy for Bladder Carcinoma In Situ Samir Bidnur Dept of Urologic Sciences, Grand Rounds March 1 st, 2017 Checkpoint Inhibition and Bladder Cancer, an evolving story with immunotherapy
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More informationInibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici
Inibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici Laura Orlando UOC Oncologia & Breast Unit Brindisi Verona 22/04/2016 Summary Studi con
More informationAtezolizumab Is a Humanized Anti-PDL1 Antibody That Inhibits the Binding of PD-L1 to PD-1 and B7.1
Phase II, Single-Arm Trial (BIRCH) of Atezolizumab as First-Line or Subsequent Therapy for Locally Advanced or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (NSCLC) Abstract 16LBA Besse B, Johnson
More informationImmunotherapy for Metastatic Malignant Melanoma. Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg
Immunotherapy for Metastatic Malignant Melanoma Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg Survival in Melanoma by Stage Proportion Surviving 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 Stage
More informationDISCLOSURES. Roche/MSD-Merck/Celgene: Research Funding
DISCLOSURES Roche/MSD-Merck/Celgene: Research Funding Roche/Celgene/AstraZeneca/Amgen/MSD/Novartis/Sanofi- Aventis/Pierre Fabré: Advisory Board or Consultant No conflict of interest with respect to this
More informationHistology independent indications in Oncology
CHMP Oncology Working Party Workshop Histology independent indications in Oncology What have we learnt from the anti PD1- PDL1 story? J Camarero (CHMP alternate ES, OncWP) Disclaimers the views presented
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationRichter s Syndrome: Risk, Predictors and Treatment
Richter s Syndrome: Risk, Predictors and Treatment 10/23/2015 John N. Allan MD Assistant Professor of Medicine Division of Hematology and Medical Oncology CLL Research Center Weill Cornell Medicine Agenda
More informationAgios Pharmaceuticals, Inc., Cambridge, MA, USA; 2. Memorial Sloan Kettering Cancer Center, New York, NY, USA [at time of work]; 3
Spotlight on Poster A071 AG-120 (ivosidenib), a first-in-class mutant IDH1 inhibitor, promotes morphologic changes and upregulates liver-specific genes in IDH1 mutant cholangiocarcinoma Yuko Ishii 1, Carlie
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationCheckpoint Inibitors for Bladder Cancer
Checkpoint Inibitors for Bladder Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow Cancer Center,
More informationBest of ASCO 2014 Sarcoma
Best of ASCO 2014 Sarcoma Robin L Jones Seattle Cancer Care Alliance University of Washington Fred Hutchinson Cancer Research Center Presentation Outline Overview progress made in sarcoma Highlight 2 trials
More informationMedia Release. Basel, 07 December 2017
Media Release Basel, 07 December 2017 Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationMelanoma: Therapeutic Progress and the Improvements Continue
Melanoma: Therapeutic Progress and the Improvements Continue David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Melanoma Research May 20, 2016 Disclosures: NONE Outline 2016 Therapeutic
More informationUK Musculoskeletal Oncology: Something for All Ages. Lars Wagner, MD Pediatric Hematology/Oncology University of Kentucky
UK Musculoskeletal Oncology: Something for All Ages Lars Wagner, MD Pediatric Hematology/Oncology University of Kentucky Pediatric-Type Sarcomas of Bone and Soft Tissue The incidence of sarcoma continues
More informationBreakthrough and Landscape of Acral and Mucosal Melanomas. Jun Guo. M.D., Ph.D Peking University Cancer Hospital & Institute
Breakthrough and Landscape of Acral and Mucosal Melanomas Jun Guo. M.D., Ph.D Peking University Cancer Hospital & Institute Current status of advanced melanoma Current status of advanced MM Targeted therapy
More informationSpecial Situation: Brain metastases
ESMO Advanced Course on Unsolved Questions in Immuno-Oncology February 16-17 2018, Amsterdam, Netherlands Special Situation: Brain metastases Matthias Preusser, MD Associate Professor of Medicine Department
More informationSystemic Therapy for Pheos/Paras: Somatostatin analogues, small molecules, immunotherapy and other novel approaches in the works.
Systemic Therapy for Pheos/Paras: Somatostatin analogues, small molecules, immunotherapy and other novel approaches in the works. Arturo Loaiza-Bonilla, MD, FACP Assistant Professor of Clinical Medicine
More informationNew Treatment Strategies in Osteosarcoma. PD Dr. Claudia Blattmann, Prof. Dr. Stefan Bielack Olgahospital Klinikum Stuttgart Germany
New Treatment Strategies in Osteosarcoma PD Dr. Claudia Blattmann, Prof. Dr. Stefan Bielack Olgahospital Klinikum Stuttgart Germany Introduction Most common bone tumor in children, adolescents and young
More informationResponse and resistance to BRAF inhibitors in melanoma
Response and resistance to BRAF inhibitors in melanoma Keith T. Flaherty, M.D. Massachusetts General Hospital Cancer Center Disclosures Roche/Genentech: consultant GlaxoSmithKline: consultant BRAF mutations
More informationColon Cancer ASCO Poster Review
Rome, February 11 th 2017 AIOM POST ASCO GI Review Colon Cancer ASCO Poster Review Lisa Salvatore UOC Oncologia Policlinico GB Rossi Azienda Ospedaliero Universitaria Integrata di Verona Me Before Me After
More informationPriming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics
Priming the Immune System to Kill Cancer and Reverse Tolerance Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Learning Objectives Describe the role of the immune system in cancer
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationBiomarkers in Imunotherapy: RNA Signatures as predictive biomarker
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction
More informationPost-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy
Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy Lee S. Schwartzberg, MD, FACP Chief, Division of Hematology Oncology; Professor of Medicine, The University of Tennessee; The West
More informationNew Therapies in HCC Bruno Sangro Clínica Universidad de Navarra. IdISNA. CIBERehd. Pamplona, Spain
New Therapies in HCC Bruno Sangro Clínica Universidad de Navarra. IdISNA. CIBERehd. Pamplona, Spain PHC 2018 - www.aphc.info EASL-EORTC Guidelines EASL EORTC Guidelines. J Hepatol. 2012;56:908-43. Systemic
More informationOpen Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD
Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Hanahan and Weinberg, 2000 Acquired Capabilities of Cancer Clinical Trials When should I consider a clinical trial? How do I find the right
More informationNewLink Genetics Corporation
Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking
More informationFifteenth International Kidney Cancer Symposium
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationLiver Cancer. Su Jong Yu, M.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine
Liver Cancer Su Jong Yu, M.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Primary Liver Cancer Hepatocellular carcinoma (HCC) : > 80% Derived
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More information